(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 108.61% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $17,556,000.On average, 7 Wall Street analysts forecast TNXP's revenue for 2026 to be $555,839,790, with the lowest TNXP revenue forecast at $467,719,042, and the highest TNXP revenue forecast at $736,465,006. On average, 6 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,283,441,711, with the lowest TNXP revenue forecast at $784,797,515, and the highest TNXP revenue forecast at $2,217,843,643.
In 2028, TNXP is forecast to generate $2,649,839,350 in revenue, with the lowest revenue forecast at $1,640,308,423 and the highest revenue forecast at $5,121,779,361.